# Neomorph, Inc.

> Neomorph is a San Diego clinical-stage biotech building molecular glue degraders - small molecules that recruit the cell's own disposal machinery to destroy disease-driving proteins long written off as 'undruggable.' Founded in 2020 out of Deerfield Management with scientific founders who decoded how thalidomide-class drugs work, the company has assembled what it calls the world's largest proprietary molecular glue target space across a broad portfolio of E3 ubiquitin ligases. It has signed multibillion-dollar discovery pacts with AbbVie, Novo Nordisk, and Biogen, dosed its first patient with lead candidate NEO-811 in kidney cancer, and raised roughly $209M across Series A and B.

- **Founded:** 2020
- **Headquarters:** San Diego, California, United States
- **Founders:** Philip Chamberlain (Co-founder, CEO (formerly President & Chief Scientific Officer); ex-Celgene cereblon pioneer), Eric Fischer (Scientific co-founder; Dana-Farber researcher who solved the DDB1-CRBN-thalidomide structure), Benjamin Ebert (Scientific co-founder; chair of Medical Oncology, Dana-Farber; defined lenalidomide's degradation mechanism), Scott Armstrong (Scientific co-founder; Dana-Farber pediatric oncology leader)
- **Team size:** ~85 employees
- **Products:** Molecular glue discovery platform, NEO-811, Partnered discovery programs
- **Notable:** Built what it describes as the world's largest proprietary molecular glue target space across multiple novel degrons and E3 ligases., Signed three multibillion-dollar pharma collaborations (AbbVie, Novo Nordisk, Biogen) within roughly five years of founding., Dosed first patient with lead candidate NEO-811 in a Phase 1/2 kidney cancer trial.

## Products & services

- **Molecular glue discovery platform** — A proprietary engine combining novel degrons, unique glue chemistry libraries, structural biology (cryo-EM, crystallography), high-throughput screening and machine learning to design molecular glue degraders across an expansive portfolio of E3 ubiquitin ligases.
- **NEO-811** — Lead investigational molecular glue degrader; first patient dosed in a Phase 1/2 trial in locally advanced or metastatic non-resectable clear cell renal cell carcinoma (kidney cancer).
- **Partnered discovery programs** — Multi-target molecular glue degrader programs run with AbbVie (oncology, immunology), Novo Nordisk (cardiometabolic, rare disease) and Biogen (Alzheimer's, rare, immunological disease).

## Achievements

- Built what it describes as the world's largest proprietary molecular glue target space across multiple novel degrons and E3 ligases.
- Signed three multibillion-dollar pharma collaborations (AbbVie, Novo Nordisk, Biogen) within roughly five years of founding.
- Dosed first patient with lead candidate NEO-811 in a Phase 1/2 kidney cancer trial.
- Raised approximately $209M total across Series A ($109M) and Series B ($100M).
- Founding science includes the landmark DDB1-CRBN-thalidomide structure (Nature 2014) and discovery of lenalidomide's degradation mechanism (Science 2014).

## Latest updates

- **2026-04** — Closed $100M Series B led by Deerfield with Regeneron Ventures, Longwood Fund, Alexandria Venture Investments and Dana-Farber's Binney Street Capital.
- **2026-04** — Announced first patient dosed in Phase 1/2 trial of NEO-811 in clear cell renal cell carcinoma.
- **2025-01** — Announced collaboration with AbbVie for molecular glue degraders in oncology and immunology (up to ~$1.64B).
- **2024-03** — Announced multi-target collaboration with Novo Nordisk for cardiometabolic and rare diseases (~$1.46B potential).

## Links

- Website: https://neomorph.com
- LinkedIn: https://www.linkedin.com/company/neomorph-llc/
- Twitter/X: https://x.com/neomorphinc

---

Profile page: https://yespress.io/neomorph-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-13